Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea
Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea: A Pilot Trial
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Liset Chacin
- Numéro de téléphone: 617-264-5926
- E-mail: lchacin@bwh.harvard.edu
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02461
- Recrutement
- Brigham and Women's Hospital
-
Contact:
- John Barbieri, MD, MBA
- Numéro de téléphone: 617-264-5926
- E-mail: jbarbieri@bwh.harvard.edu
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults aged 18 years of age and older
- Dermatologist confirmed diagnosis of rosacea
- Clinician's Erythema Assessment of at least 3 (moderate to severe disease)
- Willingness to adhere to current rosacea regimen without additions or laser treatments (e.g. PDL) during the study period.
Exclusion Criteria:
- Changes to rosacea regimen (prescription topical or oral medications) within 4 weeks of randomization.
- Facial hair, tattoos, or other characteristics that would interfere with erythema assessments
- History of symptomatic cardiac arrythmias (e.g. heart block, sick sinus syndrome, bradyarrhythmia)
- Presence of a pacemaker, implanted defibrillator, or neurostimulator
- Seizure disorder or epilepsy
- Trigeminal Neuralgia within the past year
- Severe coronary disease or recent myocardial infarction within the past 5 years
- Severe autonomic dysfunction (e.g., frequent syncope, hospitalization)
- History of recurrent syncope or unexplained fainting
- Use of brimonidine or oxymetazoline within the past 4 weeks
- Use of beta-blockers, anticholinergics, or vagal-modulating drugs within the past 4 weeks
- Severe phymatous rosacea
- Ear deformity, piercings, or other condition that prevents the use of the taVNS device
- Known hypersensitivity to electrode materials
- Patients who are pregnant.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Rosacea
|
This project consists of a 4-week trial of transaricular vagus nerve stimulation (taVNS) for rosacea.
Participation is expected to last for a total duration of 8 weeks (4 week active intervention period)
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline to week 4 of Clinician's Erythema Assessment (CEA)
Délai: Week 4
|
The CEA is a static 5-point grading scale of facial erythema severity.
The scale is 0 to 4. A positive result, means that the erythema, redness was reduced.
A negative result indicates that the erythema increased.
|
Week 4
|
|
Change from baseline to week 4 in the Dermatology Quality Life Index (DLQI)
Délai: Week 4
|
The DLQI is a dermatology-specific quality of life instrument to measure the impact of skin disease on different aspects of health-related quality of life.
The questionnaire contains 10 questions, each scored on a 4-point Likert scale.
The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.
|
Week 4
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in the Dermatology Quality Life Index (DLQI) from baseline to week 4 & 8
Délai: Week 4, Week 8
|
The DLQI is a dermatology-specific quality of life instrument to measure the impact of skin disease on different aspects of health-related quality of life.
The questionnaire contains 10 questions, each scored on a 4-point Likert scale.
The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.
|
Week 4, Week 8
|
|
Change from week 4 to week 8 in Global Flushing Severity Score (GFSS) from baseline to week 4 & 8
Délai: Week 4, Week 8
|
The GFSS is a 0-10 numeric rating scale assessing facial flushing symptoms including redness, warmth, tingling, or itching over the past 24 hours, with scores ranging from: 0 (did not have), 1-3 (mild), 4-6 (moderate), 7-9 (severe), 10 (extreme).
|
Week 4, Week 8
|
|
Change from in Patient Health Questionnaire-9 (PHQ-9) scale from baseline to week 4 & 8
Délai: Week 4, Week 8
|
The PHQ-9 is a widely used tool for assessing depression severity, with scores ranging from 0 to 27 based on the frequency of symptoms over the past two weeks
|
Week 4, Week 8
|
|
Change in Generalized Anxiety Disorder-7 (GAD-7) scale from baseline to week 4 & 8
Délai: Week 4, Week 8
|
The GAD-7 evaluates anxiety severity with scores ranging from 0 to 21, using a similar structure to the PHQ-9.
Scores are categorized as minimal (0-4), mild (5-9), moderate (10-14), and severe (15-21).
|
Week 4, Week 8
|
|
Change of Clinician's Erythema Assessment (CEA) scale from baseline to week 4 & 8
Délai: Week 4, Week 8
|
The CEA is a static 5-point grading scale of facial erythema severity.
The scale is 0 to 4. A positive result, means that the erythema, redness, was reduced.
A negative result indicates that the erythema increased.
|
Week 4, Week 8
|
|
DermSat-7 score at week 4 & week 8
Délai: Week 4, Week 8
|
The DermSat7 is a 7-item, self-administered questionnaire designed to assess patient satisfaction with dermatologic treatments.
It covers three domains - effectiveness (3 items), convenience (3 items), and overall satisfaction (1 item) - with responses on a 5-point (or 5-point) satisfaction scale, then transformed into a 0-100 scale so that higher scores indicate greater satisfaction.
|
Week 4, Week 8
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 2026P000835
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .